A Novel Chemosynthetic Peptide with β-Sheet Motif Efficiently Kills Klebsiella pnuemoniae in a Mouse Model by Tan, Shirui et al.
University of North Dakota 
UND Scholarly Commons 
Chemistry Faculty Publications Department of Chemistry 
2-9-2015 
A Novel Chemosynthetic Peptide with β-Sheet Motif Efficiently 
Kills Klebsiella pnuemoniae in a Mouse Model 
Shirui Tan 
Changpei Gan 
Rongpeng Li 
Yan Ye 
Shuang Zhang 
See next page for additional authors 
Follow this and additional works at: https://commons.und.edu/chem-fac 
 Part of the Chemistry Commons 
Recommended Citation 
Tan, Shirui; Gan, Changpei; Li, Rongpeng; Ye, Yan; Zhang, Shuang; Wu, Xu; Yang, Yi Yan; Fan, Weimin; and 
Wu, Min, "A Novel Chemosynthetic Peptide with β-Sheet Motif Efficiently Kills Klebsiella pnuemoniae in a 
Mouse Model" (2015). Chemistry Faculty Publications. 15. 
https://commons.und.edu/chem-fac/15 
This Article is brought to you for free and open access by the Department of Chemistry at UND Scholarly 
Commons. It has been accepted for inclusion in Chemistry Faculty Publications by an authorized administrator of 
UND Scholarly Commons. For more information, please contact zeineb.yousif@library.und.edu. 
Authors 
Shirui Tan, Changpei Gan, Rongpeng Li, Yan Ye, Shuang Zhang, Xu Wu, Yi Yan Yang, Weimin Fan, and Min 
Wu 
This article is available at UND Scholarly Commons: https://commons.und.edu/chem-fac/15 
© 2015 Tan et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0)  
License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further 
permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on 
how to request permission may be found at: http://www.dovepress.com/permissions.php
International Journal of Nanomedicine 2015:10 1045–1059
International Journal of Nanomedicine Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
1045
O r I g I N a l  r e s e a r c h
open access to scientific and medical research
Open access Full Text article
http://dx.doi.org/10.2147/IJN.S73303
a novel chemosynthetic peptide with β-sheet 
motif efficiently kills Klebsiella pneumoniae 
in a mouse model
shirui Tan1,2,*
changpei gan1,3,*
rongpeng li1
Yan Ye1
shuang Zhang1,3
Xu Wu1
Yi Yan Yang4
Weimin Fan5
Min Wu1
1Department of Basic sciences, school 
of Medicine and health sciences 
University of North Dakota, Grand 
Forks, ND, USA; 2laboratory of 
Biochemistry and Molecular Biology, 
school of life sciences, Yunnan 
University, Kunming, People’s republic 
of China; 3state Key laboratory 
of Biotherapy, West china hospital, 
sichuan University, chengdu, People’s 
Republic of China; 4Institute of 
Bioengineering and Nanotechnology, 
The Nanos, Singapore; 5Program 
of Innovative cancer Therapeutics, 
First affiliated hospital of Zhejiang 
University college of Medicine, 
hangzhou, People’s republic of china
*These authors contributed equally 
to this work
Abstract: Klebsiella pneumoniae (Kp) is one of the most common pathogens in nosocomial 
infections and is increasingly becoming multiple drug resistant. However, the molecular patho-
genesis of Kp in causing tissue injury and dysregulated host defense remains elusive, further 
dampening the development of novel therapeutic measures. We have previously screened a series 
of synthetic antimicrobial beta-sheet forming peptides and identified a peptide (IRIKIRIK; ie, 
IK8L) with a broad range of bactericidal activity and low cytotoxicity in vitro. Here, employ-
ing an animal model, we investigated the antibacterial effects of IK8L in acute infection and 
demonstrated that peritoneal injection of IK8L to mice down-regulated inflammatory cytok-
ines, alleviated lung injury, and importantly, decreased mortality compared to sham-injected 
controls. In addition, a math model was used to evaluate in vivo imaging data and predict 
infection progression in infected live animals. Mechanistically, IK8L can kill Kp by inhibiting 
biofilm formation and modulating production of inflammatory cytokines through the STAT3/
JAK signaling both in vitro and in vivo. Collectively, these findings reveal that IK8L may have 
potential for preventing or treating Kp infection.
Keywords: bacterial pathogenesis, inflammatory cytokines, infectious diseases, bactericidal 
activity, antimicrobial peptides, STAT3/JAK signaling transduction
Introduction
Frequent use of antibiotics in the agricultural and biomedical fields has caused a surge in 
antibiotic-resistant pathogen strains.1 Infection by multidrug resistant (MDR) bacteria, 
such as Klebsiella pneumoniae (Kp), is challenging to treat,2,3 thereby compounding 
existing conditions4 such as asthma, cystic fibrosis, and chronic obstructive pulmonary 
disease (COPD).5–7 In the United States, COPD alone causes more than 157,000 deaths 
every year.8 Kp is the third most isolated microorganism in blood cultures from patients 
with various complications.9 Therefore, understanding the mechanism of Kp antibiotic 
resistance is becoming an important topic in human health, which may provide insight 
into therapeutic strategies to control Kp infection.
To effectively eradicate antibiotic-resistant pathogens from afflicted hosts, many 
new antibacterial agents have been developed, including ertapenem,10 levaquin, and 
meropenem.11 Previously, antimicrobial peptides (AMPs) having cationic charge and 
amphipathic structures have been thought to be the best antibacterial agents thanks to 
their small size, heat stability, and broad-spectrum antibacterial activity.12 Besides, 
AMPs as endogenous antibiotics have extensive capabilities in regulating inflamma-
tion, wound repair, and the adaptive immune system in eukaryote host defense.13,14 
However, natural AMPs possess ostensible toxicity to humans and are difficult to 
prepare on a large scale.15 Although improved techniques of isolation enabled larger 
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quantity preparation, most of AMPs have been found to 
be unsuitable for clinical application due to their potential 
systemic toxicity.16 In treatment of Kp infection, the disad-
vantage of this natural peptide is its high systemic toxicity. 
Alternatively, artificially synthesized antibacterial peptides 
seem to be good candidates, as they have similar character-
istics and efficient antibacterial ability with natural AMPs.17 
However, significant toxicity to humans is still currently an 
unbridgeable gap to these artificially synthesized antibacterial 
peptides, from the laboratory to the clinic.
To overcome this limitation, the quest continues for 
artificially synthesized peptides to better control microor-
ganisms and infectious diseases. We focused on developing 
new artificially synthesized peptides with low toxicity and 
high efficacy in killing pathogenic microorganisms. Having 
previously examined bactericidal activity in vitro, we set out 
to systemically evaluate the bactericidal activity of IRIKIRIK 
(ie, IK8L) against a clinically significant pathogen Kp infec-
tion in animal models.
Materials and methods
Bacterial strains and culture conditions
K. pneumoniae (Kp; American Type Culture Collection 
[ATCC] 43816 serotype II) was obtained from Dr Virginia 
Miller (University of North Carolina, Chapel Hill, NC, USA) 
and was used for infection of mice and cells. Kp-GFP (green 
fluorescent protein) (ATCC 43816 serotype II) was kindly 
provided by Dr Steven Clegg (University of Iowa Carver Col-
lege of Medicine, Iowa City, IA, USA). Kp Xen-39 (ATCC 
93A 5370), an engineered bioluminescent pathogenic bacte-
rium strain expressing bioluminescence, was used for imag-
ing both in vitro and in vivo with Caliper’s Xenogen IVIS 
XRII optical imaging technology (Caliper; PerkinElmer, 
Waltham, MA, USA). Bacteria were grown in Luria–Bertani 
(LB) broth at 37°C for 16 hours, followed by centrifuging at 
5000 g for 5 minutes, and subsequently washed with sterile 
phosphate-buffered saline (PBS) for infection.18
Mouse infection
All animal procedures were approved by Institutional Animal 
Care and Use Committee at the University of North Dakota. 
C57BL/6J mice were purchased from Harlan Laboratory 
(Indianapolis, IN, USA). Mice were housed in a tempera-
ture- and humidity-controlled environment, and had free 
access to food and water. After anesthesia with 40 mg/kg 
ketamine, mice were instilled with 1×105 (four mice/group) 
colony-forming units (CFUs) of Kp by intranasal instillation, 
and sacrificed when they were moribund.19,20 Survival was 
determined using Kaplan–Meier curve. After bronchoalveo-
lar lavage (BAL), the lung was excised for homogenization 
or fixed in 10% formalin.
cell estimation in Bal and isolation 
of alveolar macrophages (aMs)
BAL was performed five times for each 1.0 mL (except the first 
0.6 mL) of lavage fluid; a cell smear was made from the BAL 
fluid for cell differential counting. AMs were collected from 
the BAL pellet after centrifuging at 2,000× g for 5  minutes at 
4°C and cultivated in RPMI (Roswell Park Memorial Institute) 
1640 medium supplemented with 10% newborn calf serum 
and penicillin/ streptomycin in a 5% CO
2
 incubator.
Peptide
IK8L was identified and described.21 The peptide was syn-
thesized by GL Biochem (Shanghai, People’s Republic of 
China) and purified to greater than 95% through analytical 
reverse phase high-performance liquid chromatography.
In vivo imaging
Mice were infected with bioluminescence-emitting Kp 
(Xen-39, 1×105 CFU) following anesthesia by ketamine. 
At various time points postinfection, whole body imaging 
of the infected mouse was obtained under an IVIS XRII 
system. Additionally, the distribution of Kp in various 
organs was semiquantitatively analyzed through the cal-
culated intensity of bioluminescence and also confirmed 
by direct measurement of CFUs in tissues recovered after 
imaging.22
IK8L treatment
Mice were randomly divided into a control group (n=4) 
and an IK8L-treated group (n=4). The IK8L-treated group 
received IK8L suspension (20 mg/kg body weight) through 
tail vein injection. After 4 hours, mice were infected with 
Kp by intranasal instillation.
Biofilm assays
Biofilm formation assay in test tube
Biofilm formation in test tubes was measured according to 
the method that O’Toole described previously.23 Briefly, 
test tubes were inoculated from overnight LB-grown 
bacterial cultures containing IK8L. After that, the cells 
were grown for 24 hours at 37°C; then the test tubes were 
stained with crystal violet and quantified by dissolution 
using 30% acetic acid and measured at an absorbance at 
550 nm.
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CFU of biofilms
Quantification of biofilm bacteria with or without IK8L treatment 
was performed as follows. The wells were washed six times with 
saline in order to remove any planktonic cells, 100 µL of saline 
was added to each well, and the samples were independently 
sonicated for 8 seconds by using a VC505 sonicator (Sonics and 
Materials, Inc, Newtown, CT, USA), followed by plating on agar 
dishes for 18 hours at 37°C to obtain the CFU counts.
cell infection experiments
After cultivating in LB broth at 37°C with vigorous shaking 
overnight, Kp was centrifuged at 6,000× g for 5 minutes, then 
resuspended in 5 mL fresh LB broth to grow until the mid-
logarithmic phase. The concentration of bacteria was estimated 
by reading optical density (OD) at 600 nm (0.1 OD =1×108 
cells/mL). Before infection, cells were washed once with PBS, 
and replaced with both serum and antibiotic-free medium imme-
diately. Macrophage cells were infected by Kp at the multiplicity 
of infection (MOI) of 10:1 bacteria–cell ratio for 1 hour and then 
washed three times with PBS to remove the free bacteria. Bacteria 
on the surface of the cells were killed by adding 100 µg/mL of 
polymyxin B and incubated for another 1 hour. The amount of 
the intracellular bacteria was determined by CFU counts.22,24
cell culture
AMs were isolated from the bronchoalveolar lavage fluid 
(BALF). By centrifuging at 2000 rpm, the pellet was resus-
pended and cultured in RPMI 1640 medium containing 10% 
newborn bovine serum (HyClone Laboratories, Logan, UT, 
USA) and 100 U/mL of penicillin/streptomycin (Life Tech-
nologies, Rockville, MD, USA) in a 37°C incubator with 
5% CO
2
. Mouse alveolar macrophage cell line (MH-S) was 
obtained from American Type Culture Collection (ATCC, 
Manassas, VA, USA) and maintained following the manu-
facturer’s instructions.
3-(4,5-dimethyl-2-thiazolyl)-2,5- 
diphenyltetrazolium bromide assay
This assay measures color change of 3-(4,5-dimethyl-2-
thiazolyl)-2,5-diphenyltetrazolium bromide (MTT) upon 
reduction by enzymes to assess the viability of AM. AM 
cells were obtained from infected mice and processed as 
above. Then, 1 µg/mL MTT dye (final concentration) was 
added to each well. The cells were incubated at 37°C until 
the color change occurred. The dye was reduced to form a 
purple formazan product inside living cells. Stop solution 
(10% dimethyl sulfoxide [DMSO]; 10% sodium dode-
cyl sulfate (SDS) in 50 mM HEPES (2-[4-(2-Hydroxyethyl)-
1- piperazinyl] ethanesulfonic acid) buffer) was added to 
dissolve the formazan product, and the absorbance was 
quantified by measuring a wavelength of 560 nm using a 
spectrometer plate reader.25
Nitroblue tetrazolium assay
This assay was used to determine the production of super-
oxide anion in AM cells. AM cells from BAL were grown 
in a 96-well plate in serum-containing medium at 37°C for 
4 hours. We added 1 µg/mL nitroblue tetrazolium (NBT) 
dye (Sigma, St Louis, MO, USA) to each well. The cells 
were incubated at 37°C for 1 hour or until color developed. 
The dye is yellow and gives a blue color formazan product 
upon reduction by superoxide. The reaction was terminated 
by adding 100 µL of stop solution (10% DMSO; 10% SDS 
in 50 mM HEPES buffer). The plate was left at room tem-
perature overnight for complete dissolution of formazan, and 
absorbance at 560 nm was recorded using a multiscan plate 
reader to quantify the concentration of superoxide anion. 
Triplicates were done for each sample and control.26
Tissue myeloperoxidase assay
Samples were homogenized in 50 mM hexadecyltrimeth-
ylammonium bromide, 50 mM KH
2
PO4, pH 6.0, 0.5 mM 
EDTA (ethylenediaminetetraacetic acid) at 1 mL/100 mg 
of tissue and centrifuged for 15 minutes at 12,000 rpm at 
4°C. Supernatants were decanted, and 100 µL of reaction 
buffer (0.167 mg/mL O-dianisidine, 50 mM KH
2
PO4, pH 
6.0, 0.0005% mM H
2
O
2
) was added to 100 µL of sample. 
Absorbance was read at 460 nm at 2-minute intervals. Dupli-
cates were done for each sample and control.27
Dihydrodichlorofluorescein diacetate assay
Dihydrodichlorofluorescein diacetate (H
2
DCF-DA) dye 
(Molecular Probes, Carlsbad, CA, USA) does not normally 
fluoresce but emits green fluorescence upon reaction with cel-
lular superoxide. AM cells were obtained from Kp-infected 
mice and an equal amount of dye (1 µg/mL) was added. 
After 1 hour incubation, fluorescence was measured by a 
fluorescence plate reader (BioTek, Winooski, VT, USA) 
using 485 nm excitation and a 528 nm emission filter.28
histological analysis
The lung was fixed in 10% formalin using a routine histologic 
procedure. Ten microlitres of BAL and blood were applied 
evenly on microscope slides. The formalin-fixed tissues were 
used for hematoxylin and eosin (H&E) staining to examine tis-
sue damage postinfection. After Hema staining (Thermo Fisher, 
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Waltham, MA, USA), the number of polymorphonuclear 
 neutrophils (PMN) were counted using a light microscope.
Cytokine profiling
We measured cytokine concentrations in the first 0.6 mL of 
BAL fluid (which could reflect the original levels in the lung) 
collected at the indicated times after infection by standard 
enzyme-linked immunosorbent assay (ELISA) kits follow-
ing the manufacturer’s instructions (eBioscience Inc., San 
Diego, CA, USA).18–20,29,30
Western blotting
Lung tissues were lysed and homogenized in a radioimmu-
noprecipitation assay containing a protease inhibitor cocktail 
(Sigma, St Louis, MO, USA). The supernatants were col-
lected and the protein concentration was quantitated. The 
lysates were boiled for 10 minutes, and an equal amount of 
each sample was applied to 12% SDS-polyacrylamide mini 
gels and electrophoresed. β-actin was used as a loading 
control, whereas different primary antibodies were used to 
determine the protein levels in each sample.31,32
confocal laser scanning microscopy
Cells were cultured in glass-bottomed dishes (MatTek, 
Ashland, MA, USA) for immunostaining following the 
manufacturer’s instructions. For lipid raft staining, the cells 
were added with cholera toxin B chain (CTB) (red) contain-
ing fluorescein to track sphingolipid-rich lipid rafts.33 The 
images were obtained by LSM 510 Meta confocal microscope 
(Carl Zeiss Microimaging, Thornwood, NY, USA).
Flow cytometry assay
AM cells were treated with IK8L or various controls in a 
glass-bottomed plate for 4 hours. Apoptotic cells were stained 
by Annexin V-fluorescein isothiocyanate-stained cells and 
analyzed by flow cytometry (BD Biosciences, San Jose, CA, 
USA).34
statistical analysis
Each experiment was conducted in triplicate. The differences 
in outcomes of the IK8L-treated mice were presented as 
percent or amount of change compared to the control after 
Kp infection. Data were analyzed by one-way analysis of 
variance (ANOVA) (Tukey’s post hoc) or Mann–Whitney 
U-test using GraphPad software.35,36 The survival rate was 
calculated using a Kaplan–Meier curve, with P,0.05 being 
significant from a log-rank test.37
Results
Peptide (IK8L) decreased mortality rates 
and infection severity of Kp-infected mice
We have recently reported the design of a short β-sheet 
forming peptide IK8L that is made of eight natural L-amino 
acids and demonstrates extensive and highly selective anti-
bacterial activity against clinically isolated MDR bacteria, 
and its median lethal dose in mice through tail vein injec-
tion was 35.2 mg/kg.38 To assess the physiological function 
of IK8L in vivo bacterial infection, IK8L was injected into 
C57BL/6J mice. The mice were then intranasally instilled with 
Kp Xen-39 at 1×105 CFU in 50 µL of PBS per mouse (four 
mice per group).19 Although the distribution of the bacteria 
in the enterocelia was somewhat variable, the infected mice 
exhibited much wider dissemination of bioluminescence in 
the area of thoracic cavity 4 hours postinfection with in vivo 
dynamic analysis using an IVIS XRII 200 biophotonic imager. 
However, the dissemination areas in infected mice were more 
constrained and only localized in one lung in IK8L-treated 
mice than those of sham-treated mice (Figure 1A). In order to 
predict the infection level, a math model of the relative lumi-
nescence unit counts (LUC) units vs time in the Kp Xen-39 
infected mice was applied to our experiment. The LUC units 
in the first 12 hours after the infection were collected from the 
IVIS XRII 200 biophotonic imager. The regression equations 
for sham-treated and IK8L-treated groups were
 y=92967+47002x (1)
and
 y=52770+6546x,  (2)
respectively (Figure S2A), where the x axis represents 
infection time and the y axis represents the level of infec-
tion. These equations suggest that bacterial dissemination 
is dependent on the diffusing force in a constant manner. It 
is possible that these two equations can predict the relative 
LUC units over a long period of time. According to the 
equations, the LUC units at 24 hours, 36 hours, 48 hours, 
and 50 hours were predicted (Figure S2B). The results of 
the infected mice by Kp Xen-39 of 1×105 CFU showed that 
the actual values were highly comparable to the predicted 
values at each of the corresponding time points (Figure S2B). 
Overall, the math model used here may enable the predic-
tion of infection levels in a long time period. Apparently, 
much broader infection areas were observed in control 
mice; approximately 50% of infected mice died within 
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Figure 1 Peptide (IK8L) decreased mortality rates and disease severity in Kp-infected mice. 
Notes: (A) Whole animal imaging of bioluminescence was obtained using IVIS XRII system at different time points. Sham- and IK8L-treated mice were infected with 1×105 
cFU of Kp Xen-39 by nasal cavity (caliper) (arrows indicating Kp spread regions). (B) Kaplan–Meier survival curves were obtained (P=0.0455; 95% confidence interval: 1.041 
to 52.46, log-rank test). (C) Bacterial burdens (cFU) of Kp-infected mice treated with IK8L or control at different times. In (A), data are shown as mean ± sD/seM of n=4 
mice per group; (A–C) are representative of four mice per group. ***P,0.001; Mann–Whitney U-test.
Abbreviations: CFU, colony-forming units; h, hours; Kp Xen-39, ; Max, maximum; Min, minimum; RLU, relative LUC units; LUC, luminescence unit counts; SD, standard 
deviation; SEM, standard error of the mean.
24 hours postinfection (Figure 1B), and all infected mice 
died at 50 hours. In contrast, all mice receiving IK8L treat-
ment remained alive during the entire period of observation 
(Figure 1B). These results suggest that IK8L treatment is 
effective and improves the survival chances of infected mice. 
Furthermore, the lung homogenates were investigated for 
bacterial burdens. IK8L-treated mice exhibited significantly 
decreased CFUs of Kp compared to the control mice without 
IK8L treatment at both 8 hours and 24 hours postinfection 
(Figure 1C).
IK8L reduced AM killing after Kp  
infection in mice
Since Kp Xen-39 was an engineered bioluminescent bacterium 
for imaging analysis, we next chose the widely used Kp and 
Kp-GFP strain to explore the pathogenesis mechanisms of IK8L 
against Kp infection. AM cells are key immune cells against 
Gram-negative bacterial infection. AM cells were isolated from 
the infected mice using BAL and evaluated for their viability. 
The viability of AM was increased by approximately three-
fold in IK8L-treated mice compared to untreated mice both at 
24 hours and 48 hours postinfection (Figure 2A), indicating 
that IK8L treatment increased AM survival during Kp infec-
tion. PMN in the lung and blood was analyzed at 8 hours and 
24 hours postinfection.18 Cell apoptosis was determined by flow 
cytometry using Annexin V/propidium iodide double staining, 
which showed a significant decrease in the apoptotic population 
in IK8L-treated group (3.23%) compared to the sham control 
group (51.53%) (Figure 2B). PMN penetration was also lower 
in both the BAL fluid and blood of IK8L-treated mice than that 
of sham-treated mice (Figure 2C and D). In addition, PMN in 
the BAL fluid of the control mice increased with time, while 
that in the peptide-treated mice was effectively suppressed from 
24 to 48 hours postinfection (Figure 2C). As phagocyte-derived 
reactive oxygen species (ROS) is of crucial importance against 
bacterial infections,39 ROS levels in AM cells of Kp-infected 
mice were assessed at 8 hours and 24 hours postinfection by an 
NBT assay. ROS was decreased in AM cells from IK8L-treated 
mice compared to control mice, which might lead to reduced 
production of superoxide dismutase (Figure 2E). To further 
ascertain this finding, a sensitive assay, H
2
DCF-DA, was also 
used to quantify superoxide in AMs. Indeed, the production 
of superoxide in IK8L-treated mice was reduced compared to 
sham-treated mice (Figure 2F).
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Figure 2 IK8L increased AM viability in Kp-infected mice.
Notes: (A) Cell viability was determined in AMs by MTT assay. AM cells were obtained separately from infected mice and IK8L-treated mice. The absorbance of each sample 
was recorded at 560 nm to determine the cell viability rate. (B) Scattered distribution graph of apoptotic staining of the AM cells with or without IK8L treatment. The data 
of apoptotic percentage of treated cells vs the control are representative of two experiments (arrows indicating the apoptotic levels). (C and D) PMN infiltration in the BAL 
and blood was counted by hema staining (Thermo Fisher, Waltham, Ma, Usa). (E) superoxide production in aM cells detected using an NBT assay. (F) Oxidative stress in 
aM cells was determined by h2DcF assay. Data are shown as mean ± seM of n=3 samples and are representative of three independent experiments. **P,0.01; ***P,0.001; 
one-way ANOVA (Tukey’s post hoc). 
Abbreviations: AM, alveolar macrophage; ANOVA, analysis of variance; BAL, bronchoalveolar lavage; h, hours; H2DCF, dihydrodichlorofluorescein diacetate; Kp, Klebsiella 
pneumoniae; MTT, 3-(4,5-dimethyl-2-thiazolyl)-2,5 diphenyltetrazolium bromide; NBT, nitroblue tetrazolium; PMN, polymorphonuclear neutrophil; Q, quarter; RFU, relative 
fluorescence units; RLU, relative LUC units; SEM, standard error of the mean.
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IK8L decreased infection-induced 
tissue injury
To further assess the tissue damage, the morphological 
alterations in the lung of infected mice were next investigated 
by H&E staining. As shown in Figure 3A, the infected mice 
without sham-treated bacteria exhibited apparent signs of 
inflammatory response, tissue damage, and severe pneumo-
nia. In contrast, the lungs of IK8L-treated mice had lower 
inflammatory features, including PMN penetration and tissue 
damage, than the sham-treated controls. Another mortiferous 
factor for bacterial infection is bacterial dissemination from 
lungs to other organs. Bacterial dissemination can promote 
disease progression, such as bacteremia and ultimately 
sepsis.39 Therefore, bacterial burdens in the liver, spleen, 
and kidney were further examined. As compared to the lungs 
(Figure 1C), bacterial load magnitudes in these organs were 
decreased (Figure S1A–C). Particularly, bacterial CFUs were 
significantly decreased in the liver, spleen, and kidney of 
IK8L-treated mice compared to those of sham-treated mice 
(Figure S1A–C). Myeloperoxidase (MPO) is released from 
PMN in the lung tissue in response to exposure to various 
pulmonary insults,40 which may serve as an indicator for 
infection extent. The MPO activity of the lung and other 
organs was analyzed, and it was found that MPO activity 
of the lung, liver, spleen, and kidney in IK8L-treated mice 
was significantly lower than that of sham-treated mice 
(Figure 3B–E). These findings suggest that IK8L treatment 
reduced organ damage induced by Kp infection.
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Figure 3 IK8L decreased infection-induced tissue injury.
Notes: (A) Morphological evidence of lung injury and inflammatory responses as assessed by H&E staining histological analysis (20×, scale bar =50 µm, inset shows the typical 
tissue injury and inflammatory influx). (B–E) Decreased MPO in the lung, kidney, spleen, and liver of IK8L-treated mice. Data are shown as mean ± seM of n=3 mice per 
group and are representative of three independent experiments. *P,0.05; **P,0.01; ***P,0.001; one-way ANOVA (Tukey’s post hoc). 
Abbreviations: ANOVA, analysis of variance; h, hours; H&E, hematoxylin and eosin; MPO, myeloperoxidase; RLU, relative LUC units; SEM, standard error of the mean.
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Figure 4 IK8L killed Kp by blocking biofilm formation.
Notes: (A) Biofilm formation assessed by crystal violet staining of biofilms grown in microtiter wells for 8 hours. (B) Quantification of staining of wells in (A) after 
solubilization with acetic acid and measurement of OD550. (C) CFU per well of biofilm bacteria.
Abbreviations: CFU, colony-forming units; Kp, Klebsiella pneumoniae; OD550, optical density at 550 nm. 
 
In
te
rn
at
io
na
l J
ou
rn
al
 o
f N
an
om
ed
ici
ne
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
13
4.
12
9.
19
3.
10
2 
on
 0
3-
De
c-
20
19
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
International Journal of Nanomedicine 2015:10submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
1052
Tan et al
A
pg
/m
L
2,000
IL-6
***
***
1,500
1,000
500
0
8 h 24 h
Sham
IK8L
B
pg
/m
L
TNF-α
***
***
2,000
1,500
1,000
500
0
8 h 24 h
Sham
IK8L
C
pg
/m
L
IL-1β
***
***
0
200
400
600
800
8 h 24 h
Sham
IK8L
R
el
at
iv
e 
de
ns
ity
1.5
**
*
*1.0
0.5
0.0
STAT3 JAK2 ERK1/2
Control
Sham
IK8L
R
el
at
iv
e 
de
ns
ity
* *
* *
*
*
0.0
0.5
1.0
1.5
2.0
JNK p-JNK p-NF-κBNF-κB IκB p-IκB
Control
Sham
IK8L
**
***
R
el
at
iv
e 
de
ns
ity
1.5
1.0
0.5
0.0
PI3K AKT
Control
Sham
IK8L
D
STAT3
Co
ntr
ol
Sh
am
IK
8L
JAK2
ERK1/2
β-actin
E Con
tro
l
Sh
am
IK
8L
NF-κB
p-NF-κB
JNK
p-JNK
IκB
p-IκB
β-actin
F
Co
ntr
ol
Sh
am
IK
8L
AKT
PI3K
β-actin
Figure 5 IK8L modulated Kp-induced inflammatory reaction via the IL-6/JAK/STAT3 signaling pathway. 
Notes: (A–C) elIsa was used to measure Il-6, TNF-α and Il-1β in BAL fluids of mice 8 hours and 24 hours post infection, respectively. (D) cell signaling proteins relating 
to the JaK2/sTaT3 signaling pathway were evaluated in lung tissue by Western blotting analysis. (E) expression and phosphorylation of signaling proteins relating to NF-κB 
transcription factor were evaluated in lung tissue by Western blotting. (F) cell signaling proteins relating to the aKT signaling pathway were evaluated by Western blot. 
β-actin was used as a loading control. Data are shown as mean ± seM of n=3 mice per group and are representative of three independent experiments. *P,0.05; **P,0.01; 
***P,0.001; one-way ANOVA (Tukey’s post hoc). 
Abbreviations: ANOVA, analysis of variance; BAL, bronchoalveolar lavage; ELISA, enzyme-linked immunosorbent assay; IL, interleukin; Kp, Klebsiella pneumoniae; SEM, 
standard error of the mean; TNF-α, tumor necrosis factor alpha; p, phosphorylation. 
IK8L killed Kp by blocking biofilm 
formation and modulated Kp-induced 
inflammatory responses via the IL-6 
signaling pathway
To explore the molecular mechanism in killing Kp, we 
detected biofilms of Kp and observed its inability to form 
biofilms when treated with IK8L (Figure 4A–C, compared 
to sham controls). Microscopy observation indicated that 
the biofilm of Kp was thinner in IK8L-treated groups than 
sham controls. Thus, these data suggest that IK8L may inter-
fere with the biological behavior of Kp, hampering biofilm 
formation. We speculate that IK8L-mediated bactericidal 
activity is at least partially related to biofilm formation.
To analyze whether IK8L may regulate inflammation dur-
ing Kp infection, we assessed various cytokines in BALF
 
by 
ELISA.41 The levels of tumor necrosis factor alpha (TNF-α), 
interleukin-6 (IL-6), and IL-1β decreased significantly in the 
BALF of IK8L-treated mice compared to those of sham-
treated mice at 24 hours postinfection (Figure 5A–C). To 
further explore the molecular bactericidal mechanism of IK8L 
in Kp-infected mice, inflammation-relevant signaling proteins 
in lung homogenates were next analyzed. First, the expression 
of STAT3, JAK2, and ERK1/2 involved in the IL-6 signaling 
pathway was examined. Kp infection increased the expres-
sion of STAT3, JAK2, and ERK1/2 in the mice compared to 
sham-treated mice. However, IK8L treatment significantly 
reduced the levels of STAT3, JAK2, and ERK1/2 compared 
to sham-treated mice, and STAT3 was even lower than in 
untreated mice (Figure 5D). The expression and phosphory-
lation of JNK, NF-κB, and IκB was also measured, which 
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showed that while the levels of JNK and IκB in IK8L-treated 
mice were similar to those of sham-treated mice following 
Kp infection, both protein expression and phosphorylation of 
NF-κB were increased by Kp infection and the increase was 
somewhat blocked by IK8L treatment (Figure 5E). These 
findings suggest that IK8L inhibited inflammatory responses 
by decreasing the expression of STAT3, JAK2, and ERK1/2, 
but did not inhibit NF-κB transcription. To validate these 
observations, the expression of other signaling proteins (AKT 
and PI3K) was also measured, and also showed similar pat-
terns as STAT3, JAK2, and ERK1/2 after IK8L treatment 
(Figure 5F). Taken together, IK8L modulated inflammatory 
responses during Kp infection through the JAK/STAT3 and 
AKT/PI3K signaling pathway.
sTaT3 signaling plays crucial roles 
in antibacterial activity of IK8L
To further confirm the crucial role of JAK/STAT3 signaling, 
the STAT3 inhibitor was used to study the signal pathway 
in murine MH-S, a widely used model for studying murine 
macrophages function.42 After 3 hours incubation with this 
inhibitor, cells were infected with Kp for 1 hour at 10:1 MOI. 
As shown in Figure 6A, IK8L-treated cells exhibited mark-
edly decreased production of ROS compared to sham-treated 
cells. However, blocking STAT3 increased production of 
ROS in IK8L-treated MH-S cells compared to control cells 
or IK8L-treated MH-S cells without blocking, as determined 
by an NBT assay (Figure 6A). Moreover, H
2
DCF-DA assay 
was also used to measure superoxide for validating the NBT 
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Figure 6 STAT3 signaling pathway played a crucial role in IK8L antibacterial function. 
Notes: (A) Superoxide production in MH-S cells significantly increased by blocking STAT3 with an inhibitor, compared to controls before peptide treatment using an NBT 
assay (1 mg/ml). The data were recorded at 560 nm absorbance. (B) Oxidative stress was increased by blocking STAT3 compared to controls before peptide treatment 
as determined by the h2DcF assay (5 µM). The fluorescence was quantified at 488 nm. (C) MTT assay indicated decreased cell viability of blocking STAT3 in MH-S cells 
compared to controls before peptide treatment. (D) Confocal fluorescence microscopy image showing Kp distributions and lipid raft staining using cTB chain (arrows 
indicating internalized Kp, scale bar =20 µm). (E) Quantification of colocalization between Kp and lipid raft from D, and expressed relative to sham-treated cell. (F) Bacterial 
burdens (cFU) of Kp-infected cells treated with IK8L and STAT3 inhibitor. The data are mean ± seM and are representative of three independent experiments (one-way 
ANOVA [Tukey’s post hoc]; asterisk compared with control; **P,0.01; ***P,0.001). 
Abbreviations: ANOVA, analysis of variance; CFU, colony-forming units; CTB, cholera toxin B; RLU, relative LUC units; H2DCF, dihydrodichlorofluorescein diacetate; 
Kp, Klebsiella pneumoniae; MH-S, murine alveolar macrophage cell line; MTT, 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyltetrazolium bromide; NBT, nitroblue tetrazolium; RFU, 
relative fluorescence units; SEM, standard error of the mean; DIC, differential interference contrast.
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data, and IK8L treatment indeed reduced the production of 
superoxide, while blocking STAT3 led to increased super-
oxide production (Figure 6B). Furthermore, the viability 
of Kp-infected cells was increased after IK8L treatment, 
while blocking STAT3 reduced cell viability compared to 
IK8L-treated cells as assessed by an MTT assay (Figure 
6C). In vivo dynamic analysis also indicates the potential 
role of IK8L in eradicating Kp in MH-S cells. MH-S cells 
were treated with IK8L (62.5 µg/mL) for 4 hours; after 3 
hours of blocking, cells were infected with Kp-GFP in a 
10:1 MOI for 2 hours. Then the cells were stained with 
lipid raft marker rhodamine-labeled CTB. Lipid rafts are 
shown to be associated with membrane signaling, including 
phagocytosis.43,44 The distribution of Kp within these cells 
was evaluated using confocal laser-scanning microscopy, 
and the bacterial amount in IK8L-treated cells was less than 
that in cells without IK8L treatment. There are more lipid 
rafts aggregates (CTB stained) in IK8L-treated cells than 
sham-treated cells, indicating that more active lipid rafts 
may contribute to enhanced antibacterial potency (Figure 
6D). Thus, we quantified the colocalization between invad-
ing Kp and lipid rafts, which showed significant overlaps 
Kp
Kp
JAK2 IK8L
STAT3
PI3K/AKT
ERK1/2
Transcription
factors Cytokines (IL-6)
IK8L
Lipid rafts
Figure 7 Schematic diagram showing how IK8L regulates the JAK/STAT3 pathway and counteracts the Klebsiella infection, especially through modulation of inflammatory 
responses.
Abbreviations: IL, interleukin; Kp, Klebsiella pneumoniae.
in IK8L-treated cells than sham-treated cells (Figure 6E). 
These data suggest that increased raft aggregates may 
facilitate bacterial killing by IK8L. Importantly, block-
ing STAT3 resulted in bacterial amounts similar to that in 
sham-treated groups (Figure 5D). To more quantitatively 
analyze the data, cell lysates were used to enumerate bacte-
rial burdens, which were in good agreement with the results 
of microscopy analysis (Figure 6F). These results indicated 
that IK8L markedly inhibited Kp survival rates in mouse 
macrophage cells. However, blocking STAT3 also increased 
Kp survival rates compared to controls without using 
STAT3 inhibitor, implying that IK8L inhibited Kp survival 
rates in a JAK/STAT3-dependent manner. Taken together, 
JAK/STAT3 signaling probably plays an essential role in 
the antimicrobial function against Kp, which is delineated 
in a schematic diagram (Figure 7).
Discussion
Recently we have designed a series of short synthetic β-sheet 
folding peptides with (X
1
Y
1
X
2
Y
2
) n sequence (X: hydropho-
bic amino acids, Y: cationic amino acid, n: the number of 
repeat units). By disrupting the bacterial membrane, IK8L 
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effectively killed clinically isolated multidrug-resistant bac-
teria, such as methicillin-resistant Staphylococcus aureus, 
Acinetobacter baumannii, Pseudomonas aeruginosa, and 
Mycobacterium tuberculosis,45 and prevented drug resistance 
development. Significantly reduced intracellular bacteria 
counts were observed after IK8L treatment in murine mac-
rophage cell line RAW264.7 with Staphylococcus aureus 
infection. IK8L was found to be optimal with abilities 
of endotoxin neutralization and biofilm eradication.21 To 
investigate whether this peptide has potential for use as an 
antibacterial agent against the difficult-to-kill Kp infection in 
clinics, the efficacy of IK8L against Kp-induced acute pneu-
monia and its role in the host defense were studied using our 
well-established mouse model.46 Our data demonstrated that 
IK8L significantly alleviated severe infection after lethal dose 
challenge in mice, leading to significantly reduced bacterial 
burdens in major organs, decreased mortality, and lowered 
inflammatory cytokine response. Furthermore, these stud-
ies suggest that IK8L may be able to eradicate the invading 
bacteria, thereby attenuating inflammatory responses and 
avoiding tissue injury.
Infection of MDR bacteria has become a global health 
issue in both communities and hospitals.47 The evolution of 
clinical strains of antibiotic-resistant bacteria has signifi-
cantly increased the risk of hospital-acquired infection.48 The 
ineffectiveness of commonly used antibacterial drugs and 
the emergence of antibiotic-resistant bacteria require new 
potent therapy for drug-resistant infections. One innovative 
approach is to use AMPs with a membrane-lytic functional 
mechanism as antibiotic agents.
In this study, the bactericidal activity of IK8L was evalu-
ated in mouse models. This peptide targeted bacterial outer 
membrane structure and showed surprisingly high efficacy 
in killing MDR Gram-positive and Gram-negative bacteria.38 
Compared to other antibacterial peptides, IK8L shows high 
sterilization activity with a broad spectrum. One typical 
antibacterial mechanism of IK8L is the membrane disruption. 
The membrane of Kp, a successful Gram-negative human 
pathogen, contains abundantly charged lipids, and these 
negative charges can significantly enhance the membrane 
binding of peptide.49 Sepsis is a grave clinical syndrome 
due to high mortality rates, resulting from an impaired host 
response to infection.50 An obvious increase in the survival 
rate of Kp-infected mice has, to our knowledge, been 
observed for the first time, indicating high efficacy of IK8L 
against Kp infection in a time- and dose-dependent manner. 
In a mouse septic model, groups treated with IK8L signifi-
cantly reduced infection levels. In the present study, a dose 
of 20 mg/kg was highly effective in vivo when administered 
intravenously. Meanwhile, we also used a math model to 
gauge infection levels over long time periods, which might 
be a potential tool to predict disease progression of Kp infec-
tion in clinics.
We also found that IK8L could slow down the forma-
tion of biofilms. As biofilm is very important for bacterial 
resistance to antibiotics and a harsh host environment, the 
peptide may be useful for controlling chronic infection 
in immunodeficient individuals. Another key finding of 
our study is that IK8L could markedly decrease cytokine 
response IL-6 in mice infected by Kp, which was observed 
both in the lungs and BAL fluids. In this model, IL-6 was 
down-regulated through a STAT3 pathway in IK8L-treated 
mice. Other reports have shown that IL-1β and TNF-α were 
important for host responses to Kp infection.51 However, 
we have found the changes of these two cytokines were 
less substantive. The detailed mechanism is unknown but 
might be due to a select impact on the production of proin-
flammatory cytokines in Kp-infected mice. Kp infection 
can significantly promote a spontaneous activation of the 
JAK/STAT pathway. However, the IK8L can downregulate 
STAT3 and ERK1/2 expression in Kp infected cells and 
organs, and subsequently inhibit the downstream signaling 
pathway factors and inflammatory reaction. These find-
ings suggest that IK8L did not inhibit NF-κB transcription 
and AKT/PI3K expression following infection. Thus, we 
speculate that there may be an interaction between STAT3 
and ERK1/2 to impact proinflammatory cytokine produc-
tion. However, how these signaling pathways regulate 
inflammatory responses is still unclear and needs additional 
validations, which may be interesting future directions for 
further research.
Due to the complexity of cell signals that may constitute 
a variety of cellular components and organ systems,52,53 
much needs to be pursued in the future to further understand 
the detailed mechanisms after in vivo peptide application. 
We used the peritoneal route to administer the peptide, 
but airway delivery may also be considered for prevent-
ing or treating lung infection, a frequent invasion route 
of Kp. It will also be interesting to test the applicability 
of the peptide in treatment of P. aeruginosa in animals, 
another successful bacterium crying for lack of effective 
vaccines.54,55 Although current studies indicate a potential 
for the peptide to be applied in prevention and treatment of 
Kp infection, we predict that there may be a long process 
before the realization of that promise, like other preventive 
and therapeutic research.53,56–59
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Conclusion
The current study has demonstrated that IK8L is highly 
effective against Kp infection in an infected-Kp mouse 
model. Since the ever-increasing multidrug resistance limits 
available therapeutic options, this novel AMP may provide 
a strategy for treating Kp or other MDR infections. Future 
studies should attempt to fully characterize the usefulness 
of antimicrobial IK8L as a clinically useful therapeutic for 
multidrug-resistant infectious diseases.
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Figure S1 IK8L decreased the dissemination of infection.
Notes: (A–C) The liver, spleen, and kidneys showed significantly decreased bacterial burdens after infection with Kp in IK8L-treated mice compared with sham-treated mice. 
IK8L-treated mice and sham-treated mice were infected with 1×105 cFU/mouse Kp at 8 and 24 hours. Fresh tissues were homogenized in PBS. The same amounts of tissue 
were evaluated for testing bacterial colonies and the unit is cFU/g. The data are representative of four mice per group. ***P,0.001; Mann–Whitney U-test.
Abbreviations: CFU, colony-forming unit; Ctrl, control; h, hours; Kp, Klebsiella pneumoniae; PBS, phosphate-buffered saline.
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Figure S2 Prediction of infection with time using the mathematical model.
Notes: (A) Data obtained from in vivo imaging were quantified using relative LUC units of the two groups in sham-treated and IK8L-treated mice at 1 hour, 2 hours, 4 hours, 
8 hours, and 12 hours. Sham- and IK8L-treated mice were infected with 1×105 cFU/mouse of Kp Xen-39 by nasal cavity. semiquantitatively, bioluminescence intensity was 
obtained using IVIs XrII software. regression equation was calculated using sPss software calculations. (B) The data showing predicted relative lUc units of two groups 
according to two regression equations in (A) at 24 hours, 36 hours, 48 hours, and 50 hours according to our regression equation. (C) The data showing actual lUc units 
of the two groups in sham-treated and IK8L-treated mice at 24 hours, 36 hours, 48 hours, and 50 hours. Sham- and IK8L-treated mice were infected with 1×105 cFU of 
Kp Xen-39 by nasal cavity.
Abbreviations: CFU, colony-forming units; LUC, luminescence unit counts.
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